FT’s rudimentary screen identifies five banks as particularly “weak.” We’ll see. Each of these banks possesses some mitigating characteristics that make them stronger than they appear to this screen. (This is not advice.)
About Us
We are your banking experts.
Private Equity: We are a trusted partner for family offices and other investors seeking to invest in U.S. banks in the private markets. We source investment opportunities and provide diligence services and ongoing monitoring of bank investments for family offices and other investors for whom we provide cost-effective confidence for their financial company investments.
Public Markets: We structure bank investment portfolios providing risk-tailored strategies by systematically integrating fundamental and technical analysis building alpha-generating long/short portfolios from the nearly 300 liquid publicly traded banking companies in the U.S. markets. If you want bank equity exposure with tailored risk parameter’s, we’re your source.
Recent Posts
- Cybiont: Large Bank Commercial Real Estate (ComRe) Update 4Q24
- Cybiont: Commercial Real Estate 3Q24 Update
- An Historic Opportunity to Renovate Bank Supervision & Regulation
- A Closer Look at Amerant Bank’s (AMTB’s) Change in Modeled Reserve Adequacy from the Previous Quarter (1Q24)
- About a quarter of U.S. publicly traded commercial banks have inadequate ACL levels
Recieve Cybiont’s analysis in your email as it’s released:
Leave a Reply